Medtronic, Inc. MDT today announced
U.S. Food and Drug Administration (FDA) 510(k) clearance and the first U.S.
clinical use of its new Affinity Pixie^® Oxygenation System. The system allows
for broader use in children of various sizes and easy set-up and use by
perfusionists during lifesaving open-heart (cardiopulmonary bypass) surgeries
in neonates, infants and small children, including those with congenital heart
defects.
The Affinity Pixie Oxygenation System serves as a child's lungs during
open-heart surgery by removing carbon dioxide and adding oxygen to the child's
blood before returning it to the body. It also cools or warms the blood to
attain the desired body temperature. During open-heart surgery, blood is
routed away from the child's heart and lungs through the cardiopulmonary
bypass circuit that includes the oxygenation system, thereby creating a
bloodless, motionless field, which is what allows surgeons to perform complex
procedures on the heart intended to correct the defect or improve heart
function.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in